Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
The net profit margin is 329.09%.
Reported quarterly profit margin; no daily interpolation. Q1 FY2027 (2026-06-30): 0.00%.
NET PROFIT MARGIN
329.09%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
0.00%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+126673.08%
vs the sector median at left
Helus Pharma Inc.
Market Cap
$669.43M
Net Profit Margin
329.09%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$669.77M
Net Profit Margin
-194.74%
TTM Avg
-217471.40%
3Y Avg
-109716.20%
5Y Avg
-73279.44%
Market Cap
$662.48M
Net Profit Margin
1.76%
TTM Avg
11.88%
3Y Avg
8.37%
5Y Avg
1.42%
Market Cap
$677.67M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$656.86M
Net Profit Margin
-6.18%
TTM Avg
-12.06%
3Y Avg
-12.06%
5Y Avg
-12.06%
Market Cap
$684.45M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-265.57%
5Y Avg
-265.38%
Market Cap
$687.69M
Net Profit Margin
-231.59%
TTM Avg
-991.98%
3Y Avg
-1206.82%
5Y Avg
-1395.31%
Market Cap
$691.64M
Net Profit Margin
-309.73%
TTM Avg
-283.95%
3Y Avg
-1263.35%
5Y Avg
-1016.41%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Helus Pharma Inc. (HELP) | $669.43M | 329.09% | 0.00% | 0.00% | 0.00% |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $669.77M | -194.74% | -217471.40% | -109716.20% | -73279.44% |
| Annexon, Inc. (ANNX)vs › | $672.57M | 0.00% | 0.00% | 0.00% | 0.00% |
| MiMedx Group, Inc. (MDXG)vs › | $662.48M | 1.76% | 11.88% | 8.37% | 1.42% |
| ArriVent BioPharma, Inc. (AVBP)vs › | $677.67M | 0.00% | 0.00% | 0.00% | 0.00% |
| Starling Oncology, Inc. (STLN)vs › | $656.86M | -6.18% | -12.06% | -12.06% | -12.06% |
| Solid Biosciences Inc. (SLDB)vs › | $684.45M | 0.00% | 0.00% | -265.57% | -265.38% |
| Verastem, Inc. (VSTM)vs › | $687.69M | -231.59% | -991.98% | -1206.82% | -1395.31% |
| Wave Life Sciences Ltd. (WVE)vs › | $691.64M | -309.73% | -283.95% | -1263.35% | -1016.41% |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $693.54M | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
317.1%
Net Profit Margin
329.1%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-10-31 | 0.00% |
| 2020-06-30 | -504.98% |
| 2019-12-31 | 0.00% |
| 2019-07-31 | 0.00% |
| 2019-04-30 | 0.00% |
| 2019-01-31 | 0.00% |
| 2018-10-31 | 0.00% |
| 2018-07-31 | 0.00% |
| 2018-04-30 | 0.00% |
| 2018-01-31 | 0.00% |
| 2017-10-31 | 0.00% |
